JAT

0.00%

75.0¢ jatcorp limited

Been watching for two years already. There’s giving yourself a...

First 52 Last

Share
Profile

Follow
BazzleDog

5,003 Posts.

11

20/02/20

20:18

Post #: 43056504
Share

Originally posted by momo_lol: ↑

I think it is too early to call this loan deal a bad deal, and too early to think the financial company going to take a big chunk at lower price, finance company aren’t stupid to lend $10m without assessing JAT’s business operations, who would say the finance company will get JAT shares? What if the load repayment done before it’s due day?

- why do you think we need that much cash for? Of course to upgrade production lines of our newly bought DAIRY CNCA credited manufacturing plant (1 of the 15s in Australia), why we do this? —> foresee able future demands as Neurio sales have been increasing quarter by quarter and year on year , the last accounts already tells you why. JAT has been mostly played by traders and traders aren’t have much money to fund business upgrades operations, traders only want to trade to get profits not hand out more money to grow the business as this isn’t their objective in trading, hence you see when fundings operations handed down to Chinese investors that traders are biarching about the dud move, and when rights issue handed down to shareholders in Aus and NZ yet people aren’t willing to take part of it. Because they only want to see JAT becoming second A2M with a magical $7m cash.

- JAT mgmt specified that most of their subsidiaries are going to be in cash positive operations within 12months that is including Neurio, GF, Vmeat and Cosmetic businesses, and we have been running on third consecutive cash positive quarters and this upcoming one should be cash positive too based on the unprecedented orders amount from Jan to March as cashed by coronavirus.

-JAT always wanted a site in Sydney but probably too expensive to get a site like ANMA 8500sm in Sydney and constrained by funding issues. Once the new plant is fully operational and max out the production lines to churn on better cash flows and I’m sure the second plant will be in their mind with potential partner of Sinopharm. Always need to start from somewhere. How much we finance for our first plant compares to other companies paid for theirs is a great deal from JAT, probably too great to believe to be true.

- Signed $80m deal probably gonna generate a reasonable chunk of cash profits to pay the current debts off and NO shares going to hand out, not a single ☝️

it is all wait and see approach I say.

Expand

Been watching for two years already. There’s giving yourself a good deal in price and then there’s snout at trough.

The company has made significant progress and I think it’s time the larger investors to take their lead boots off the back of smaller majority.

JAT Price at posting: 5.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 17 more messages in this thread...

First 52 Last

Add JAT (ASX) to my watchlist

(20min delay)
Last 75.0¢		Change 0.000(0.00%)		Mkt cap ! $62.44M

Open	High	Low	Value	Volume
75.0¢	75.0¢	73.0¢	$41.80K	55.83K

Buyers (Bids)

No.	Vol.	Price($)
1	19643	75.0¢

Sellers (Offers)

Price($)	Vol.	No.
78.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	19643	0.750
1	3846	0.650
1	17500	0.645
1	1650	0.600
1	11888	0.590

Price($)	Vol.	No.
0.780	30000	1
0.790	3655	1
0.800	22550	3
0.805	18000	2
0.820	42584	2

Last trade - 15.03pm 04/10/2024 (20 minute delay)

JAT (ASX) Chart

Been watching for two years already. There’s giving yourself a...

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Been watching for two years already. There’s giving yourself a...

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News